The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perez-Trallero, E
- Uranga, A
- Cilloniz, C
- Marimon, JM
- Cifuentes, I
- Mendez, C
Grupos
Abstract
Background: Streptococcus pneumoniae serotypes distribution in community-acquired pneumonia (CAP) requiring hospitalization in adults after introduction of PCV13 in children is not well known. Our aim was to evaluate the distribution of serotypes in pneumococcal pneumonia according to risk factors and comorbidity conditions after the introduction of PCV13 in children in 2010. Methods: A prospective study from 2011 to 2014 was performed in immunocompetent adults hospitalized with CAP in 3 Spanish hospitals. Microbiological confirmation was obtained using a serotype specific urinary antigen detection test (UAD test), Binax Now and conventional cultures. Results: 1258 adults were enrolled and pneumococcal pneumonia (invasive disease in 17.7%) was confirmed in 368 (29.3%) and 17.6% of the any-cause CAP were caused by PVC13 serotypes (3.5% PCV7 serotypes). Around 60% of pneumococcal CAP were caused by PCV13 serotypes (74.6% in invasive episodes vs 57.4% in non-invasive ones). The most prevalent serotypes in invasive disease were 1, 3, 7F, 19A and 14. No significant differences were observed in the distribution of PCV13 serotypes across the study periods. Regarding comorbidity, the rate of PCV13 serotypes was similar among them, and it was slightly higher in those with no underlying conditions. Conclusions: Serotypes included in PCV13 caused a significant proportion of CAP in adults with underlying conditions and in healthy adults, with no significant changes in cases due to PCV7 or PCV13 from 2011 to 2014, suggesting an insufficient indirect protection from childhood vaccination. Strategies for implementing pneumococcal vaccination of adults are encouraged to reduce the incidence of pneumococcal episodes. (C) 2017 Elsevier Ltd. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0264-410X, 1873-2518
- Tipo:
- Article
- Páginas:
- 5264-5270
- Factor de Impacto:
- 1,863 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Vaccine ELSEVIER SCI LTD
Citas Recibidas en Web of Science: 20
Documentos
- No hay documentos
Filiaciones
Keywords
- Pneumococcal pneumonia; PCV13 serotypes; Vaccine
Proyectos asociados
CALIDAD EN ATENCION A LA NEUMONIA GRAVE Y SU IMPACTO EN EL PRONOSTICO. VALIDACION DE NORMATIVAS SEPAR Y DE INDICADORES DE CALIDAD ASISTENCIAL
Investigador Principal: INMACULADA ALFAGEME MICHAVILLA
PI04/1150 . INSTITUTO DE SALUD CARLOS III . 2005
BIOMARCADORES INFLAMATORIOS Y CARDÍACOS COMO PREDICTORES DE EVENTOS CARDIOVASCULARES Y MORTALIDAD TRAS EL ALTA EN LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD.
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
PI13/00583 . INSTITUTO DE SALUD CARLOS III . 2014
ESTUDIO EPIDEMIOLÓGICO PROSPECTIVO PARA ESTIMAR EL IMPACTO DE LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD EN LA POBLACIÓN ADULTA DEBIDA A STREPTOCOCCUS PNEUMONIAE, MEDIANTE EL USO DE UN NUEVO TEST DIAGNÓSTICO DE DETECCIÓN DEL ANTÍGENO NEUMOCÓCICO ESPECÍFICO DE SEROTIPO EN ORINA (ESTUDIO CAPA).
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
PFI-PRE-2011-02 . 2011
ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON COMPARADOR PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DELAFLOXACINO INTRAVENOSO CON CAMBIO A VÍA ORAL EN SUJETOS ADULTOS CON NEUMONÍA BACTERIANA ADQUIRIDA EN LA COMUNIDAD.
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
ML-3341-306 . 2016
ESTUDIO ALEATORIZADO, CON ENMASCARAMIENTO Y GRUPOS PARALELOS, MULTICÉNTRICO DE BÚSQUEDA DE DOSIS, PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE DIFERENTES DOSIS DE TOBRAMICINA EN POLVO PARA INHALACIÓN EN PACIENTES CON BRONQUIECTASIA NO DEBIDA A FIBROSIS QUÍSTICA E INFECCIÓN PULMONAR POR P. AERUGINOSA
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
CTBM100G2202 . 2017
ENSAYO CLÍNICO CON ENMASCARAMIENTO DOBLE, MULTICÉNTRICO Y CONTROLADO CON PLACEBO PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE 12 MESES DE TERAPIA CON PROMIXIN® INHALADO (COLISTIMETATO DE SODIO) PARA EL TRATAMIENTO DE PACIENTES CON BRONQUIECTASIA NO DEBIDA A FIBROSIS QUÍSTICA CON INFECCIÓN CRÓNICA POR PSEUDOMONAS AERUGINOSA (P. AERUGINOSA)
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
Z7224L01 . 2017
REGISTRO ESPAÑOL INFORMATIZADO DE PACIENTES CON BRONQUIECTASIAS.
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
REGISTRO RIBRON . 2015
Cita
Menendez R,España PP,Perez E,Uranga A,Mendez R,Cilloniz C,Marimon JM,Cifuentes I,Mendez C,Torres A. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. Vaccine. 2017. 35. (39):p. 5264-5270. IF:3,285. (2).